Covidien , the demerged healthcare division of US conglomerate Tyco, will on Monday list on the New York Stock Exchange and in Bermuda with an expected valuation of about $20bn.

The move marks the last phase in the US conglomerate’s plan to split into three independent, publicly traded companies to improve investor returns.